Meeting Report

Biosimilars: Beginning a Conversation

Panelists: Christopher J. Campen,(1) PharmD, BCPS, BCOP (Moderator), Kelley D. Mayden,(2) MSN, FNP, AOCNP®, Ali McBride,(3) PharmD, BCPS, BCOP, and Michael Swit,(4) Esq.

(1) Greenville Health System, Greenville, South Carolina; (2) Wellmont Cancer Institute, Bristol, Virginia; (3) University of Arizona Cancer Center, Tucson; (4) Illumina, Inc.

Panelists' disclosures of potential conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2016;7;251–253 | doi: 10.6004/jadpro.2016.7.3.1 | © 2016 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here